NCT03694639

Brief Summary

Background:Patients underwent abdominoperineal resection with colostomy may suffered from phantom rectum pain syndrome in the perineal area.In this study, the investigators evaluate the combination between ganglion impar block to pregabaline in the treatment of phantom rectal pain syndrome. Method: Forty patients were randomly allocated into 2 groups: Group A (n=20) where patients received pregabaline 150 mg twice daily. Group B (n=20) where patients received pregabaline 150 mg twice daily plus ganglion impar block using 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jun 2018

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 12, 2018

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

September 29, 2018

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 3, 2018

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 29, 2019

Completed
Last Updated

March 7, 2019

Status Verified

March 1, 2019

Enrollment Period

12 months

First QC Date

September 29, 2018

Last Update Submit

March 6, 2019

Conditions

Outcome Measures

Primary Outcomes (2)

  • numerical rating scale

    from 0 to 10 as 0 no pain and 10 the worst pain

    two months

  • Participant satisfaction reporting scale (PSRS)

    it is 5 item self questionnaire1. How well was your pain problem explained to you during treatment?2. Did you agree with the types of treatments and recommendations that you received? 3. How satisfied were you with the care that you received in the Spine Care Center/ Anesthesiology Clinic? 4. Rate your overall improvement since starting treatment: 5. Rate your level of satisfaction with your improvement since starting treatment.

    two months

Secondary Outcomes (3)

  • Number of participants with post block complication

    2 hours

  • success rate of block

    one week

  • Pain Anxiety symptoms scale (PASS).

    one week

Study Arms (2)

Pregabaline group

NO INTERVENTION

where patients received pregabaline 150 mg twice daily.

Pregabaline plus ganglion impar block group

ACTIVE COMPARATOR

where patients received pregabaline 150 mg twice daily plus ganglion impar block using 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone.

Other: ganglion impar block

Interventions

CT sections were done in the axial plane 4 mm slice thickness to detect the site of sacrococcygeal disk. After a suitable section was confirmed, two distances were measured, one from patient's spine to the proper site of entry and the other from the site of entry to the target point.22 gauge spinal needle 12 cm was introduced until reach anterior to sacrococcygeal disk. When the needle tip location was ideal, 2 ml lidocaine mixed with1ml of radiopaque dye was injected. CT sagittal section was done to verify the retroperitoneal distribution of the dye. After good contrast spread confirmation, 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone was injected

Pregabaline plus ganglion impar block group

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • complained from phantom rectal pain syndrome after abdominoperineal surgery for rectal cancer with colostomy.

You may not qualify if:

  • those who refused to share
  • evidence of local infection at the puncture site
  • allergy to drugs used
  • patients with bleeding tendency or coagulopathy, renal or hepatic failure, cardiac patients,
  • bony abnormality and local malignant recurrence or lower vertebral metastasis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yahay wahba

Al Mansurah, Egypt

RECRUITING

MeSH Terms

Conditions

Phantom Limb

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesPain, PostoperativePostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsSigns and SymptomsPain

Central Study Contacts

Yahya Mhamed Wahba, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer of anesthesia

Study Record Dates

First Submitted

September 29, 2018

First Posted

October 3, 2018

Study Start

June 12, 2018

Primary Completion

June 1, 2019

Study Completion

July 29, 2019

Last Updated

March 7, 2019

Record last verified: 2019-03

Locations